| Product Unit Size | Cost | Quantity | Stock |
|---|
Simufilam was first introduced as having the potential to reduce biomarkers of Alzheimer’s disease. The original data has since become suspect and could not be found. Fraud charges have been filed by the SEC. Simufilam may or may not have some useful bioactivities. The proper research, with proper data collection and analysis, is still to be done.
| Cas No. | 1224591-33-6 |
|---|---|
| Formula | C15H21N3O |
| Formula Wt. | 259.35 |
| Chemical Name | 1-benzyl-8-methyl-1,4,8-triazaspiro(4.5)decan-2-one |
| IUPAC Name | 4-benzyl-8-methyl-1,4,8-triazaspiro[4.5]decan-3-one |
| Synonym | PTI-125; PTI-910; C0105; 1,4,8-Triazaspiro(4.5)decan-2-one, 8-methyl-1-(phenylmethyl)- |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet |
|---|
Pillar C. Research backing experimental Alzheimer’s drug was first target of suspicion. Science. 2022 Jul 22;377(6604):363. PMID: 35862516
Pillar C. Probe of Alzheimer’s studies finds ‘egregious misconduct’. Science. 2023 Oct 20;382(6668):251-252. PMID: 37856608
Dyer O. Scientist who worked on Cassava’s Alzheimer drug simufilam charged with fraud. BMJ. 2024 Jul 15: 386:q1568. PMID: 39009358
Frontiers Editorial Office. Expression of concern: simufilam suppresses overactive mTOR and restores its sensitivity to insulin in Alzheimer’s disease patient lymphocytes. Front Aging. 2024 Aug 22:5:1483030. PMID: 39239266
Pillar C. Firm misled investors on Alzheimer’s drug, SEC charges. Science. 2024 Oct 4;386(6717):15. PMID: 39361735